Gelesis Holdings, Inc. (GLSHQ)
OTCMKTS · Delayed Price · Currency is USD
0.00
0.00 (0.00%)
At close: Aug 29, 2024

Gelesis Holdings Company Description

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases.

It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management.

In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation.

Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Gelesis Holdings, Inc.
Country United States
Founded 2006
Industry Biotechnology
Sector Healthcare
Employees 93
CEO Yishai Zohar

Contact Details

Address:
501 Boylston Street
Boston, Delaware 02116
United States
Phone 617 456 4718
Website gelesis.com

Stock Details

Ticker Symbol GLSHQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number US36850R2040
SIC Code 2836

Key Executives

Name Position
Yishai Zohar Founder, President, Chief Executive Officer, Chief Compl. Officer, Secretary, Treasurer, Interim PFO and PAO and Director
Dr. Alessandro Sannino Ph.D. Co-Inventor and Lead Project Scientist
Joy Bauer M.S., RDN Chief Nutrition Officer of Plenity